Befejeződött1/2. fázis
A Study to assess the safety and potential use of GEH121224 (18F) Injection to visualise HER2-Receptor expression using PET imaging in patients with Metastatic Breast Cancer
Key facts
- Where
- Huddinge, SvédországSee the site
- Phase
- 1/2. fázis
Where in Svédország
- Karolinska University HospitalHuddinge, SvédországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GE Healthcare Limited
- Trial code
- EU 2023-507720-23-00
- Record updated
- 2025. június 27.